Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / COM
-
Shares outstanding
-
66.4M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
59.5M
-
Shares change
-
+13.5M
-
Total reported value, excl. options
-
$1.45B
-
Value change
-
+$425M
-
Put/Call ratio
-
0.44
-
Number of buys
-
68
-
Number of sells
-
-37
-
Price
-
$24.50
Significant Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) as of Q3 2022
131 filings reported holding RYTM - RHYTHM PHARMACEUTICALS, INC. - COM as of Q3 2022.
RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.5M shares
of 66.4M outstanding shares and own 89.59% of the company stock.
Largest 10 shareholders include PRIMECAP MANAGEMENT CO/CA/ (7.03M shares), FEDERATED HERMES, INC. (6.31M shares), BAKER BROS. ADVISORS LP (6.06M shares), RA CAPITAL MANAGEMENT, L.P. (5.47M shares), NEA Management Company, LLC (4.91M shares), GOLDMAN SACHS GROUP INC (4.78M shares), BlackRock Inc. (3.54M shares), STATE STREET CORP (3.13M shares), VANGUARD GROUP INC (2.23M shares), and Frazier Life Sciences Management, L.P. (1.89M shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.